Buy Semax 1%, 60 mg

€39.54

Semax 1%, 60 mg, is a formulation-dependent heptapeptide research reagent for analytical and in vitro laboratory work. Pharma Research .eu should provide verified active content, sequence, HPLC purity and LC-MS identity before European procurement.

Category:
Description

Buy Semax 1% 60 mg for Advanced Laboratory Research in Europe

Semax is a synthetic seven-residue peptide commonly represented as H-Met-Glu-His-Phe-Pro-Gly-Pro-OH. A 1% presentation containing 60 mg of Semax corresponds to a nominal 0.6 mg peptide content per 60 mg of finished formulation; however, the product matrix, total volume or mass and excipients must be confirmed before publication. The free peptide is reported as C₃₇H₅₁N₉O₁₀S, with average molecular mass approximately 813.9 Da and CAS Registry Number 80714-61-0. Pharma Research .eu presents this material for qualified European laboratory teams requiring documented peptide reagents.artemispeptides+1

Uncompromising Purity and Analytical Characterisation

Semax should be specified as the linear heptapeptide:

H-Met-Glu-His-Phe-Pro-Gly-Pro-OH

The free N-terminus and free C-terminal carboxylic acid should be stated explicitly. N-acetyl Semax, Semax amidate, N-acetyl Semax amidate and Semax acetate are different chemical forms with different molecular formulae, masses and analytical behaviour. They must not be presented as equivalent to the free peptide.

The phrase β€œSemax 1%, 60 mg” requires clarification. It may describe a 60 mg bulk presentation with 1% active peptide, a 1% liquid preparation containing 60 mg of total material, or an informal product title. A compliant product page should state the exact peptide mass, total formulation mass or volume, solvent, excipients and packaging configuration. If 60 mg refers to the peptide itself, it should not be described as a 1% preparation without the total formulation quantity.

For laboratory procurement, the appropriate target is β‰₯99.0% purity by RP-HPLC for the peptide fraction, subject to confirmation by the actual lot-specific certificate of analysis. Research references commonly report Semax at approximately 99% purity with CoA documentation, but the batch chromatogram and identity data should control acceptance.pekcuralabs+1

A complete CoA should include:

  • RP-HPLC purity percentage for the peptide fraction.

  • Chromatographic method and representative chromatogram.

  • LC-MS, ESI-MS or high-resolution MS identity confirmation.

  • Sequence and terminal-group designation.

  • Free-peptide, acetate or other salt-form information.

  • Assay of active peptide content in the 1% formulation.

  • Excipients, solvent and total preparation volume or mass.

  • Residual-solvent results from synthesis and purification.

  • Water or residual-moisture content, where measured.

  • Heavy-metal or elemental-impurity results where included in the quality programme.

  • Lot number, manufacture date, retest date and storage conditions.

The commonly reported free-peptide formula is C₃₇H₅₁N₉O₁₀S, with average molecular mass approximately 813.9 g/mol and monoisotopic mass near 813.3480 Da. Semax acetate has different reported composition and mass, so the supplier must identify the supplied chemical form.artemispeptides+1

The physical appearance depends on the formulation. The neat peptide is generally a white to off-white lyophilised solid. A 1% product may instead be a clear or slightly opalescent liquid, depending on its solvent, buffer and excipients. Appearance should be verified against the batch specification and should not be used as a substitute for HPLC, mass spectrometry or assay-content testing.

High purity and accurate active-content measurement are essential because methionine may undergo oxidation, while incomplete synthesis, terminal-group variants and residual reagents can produce closely related impurities. In a 1% formulation, inaccurate peptide-content assignment or matrix interference can also create substantial concentration errors. Lower-grade or poorly documented material may be unsuitable for quantitative LC-MS, stability-indicating methods or reproducible in vitro comparisons.

Principal Laboratory Applications and Research Methodologies

Semax is suitable for controlled laboratory research involving modified ACTH-fragment chemistry, peptide analytics and in vitro neurobiological model development. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.

RP-HPLC and LC-MS method development. Semax can be used as a defined peptide analyte for retention-time assignment, intact-mass confirmation, impurity profiling and assay-content determination. Analytical methods should distinguish free Semax from acetate, acetylated or amidated variants and from oxidation products.

Formulation assay and uniformity testing. A 1% preparation requires quantitative verification of active peptide content, homogeneity and recovery. Laboratories may assess assay concentration, between-container uniformity, solvent compatibility and changes during storage. The formulation matrix should be analysed separately to identify background peaks or ion-suppression effects.

Comparative peptide-stability research. Researchers may compare free Semax with terminally modified analogues under controlled temperature, pH, light and oxidative conditions. Methionine oxidation should be monitored using HPLC and mass spectrometry, and any apparent loss should be distinguished from adsorption or incomplete dissolution.

In vitro biochemical and cellular models. A verified preparation may be incorporated into controlled cell-free or cellular systems examining peptide-associated signalling or neurotrophic read-outs. Experimental plans should include vehicle and matrix controls, concentration confirmation and independent confirmation that the 1% formulation does not alter the assay endpoint.

If 60 mg represents the total formulation and the concentration is genuinely 1% w/w, the nominal Semax content would be 0.6 mg. If 60 mg represents active peptide, the product contains 60 mg of Semax and cannot simultaneously be called a 1% preparation without a total formulation mass of 6 g. This distinction must be resolved before displaying the product specification.

The product should not be marketed with a nominal molar concentration until the active peptide content, final volume, salt form and formulation matrix are documented. Using the free-peptide mass of 813.9 g/mol, 0.6 mg corresponds to approximately 0.737 Β΅mol, whereas 60 mg corresponds to approximately 73.7 Β΅mol.

Compound Stability, Optimal Storage, and Safe Handling Protocols

For neat lyophilised Semax, research references commonly recommend storage at approximately βˆ’20Β°C in a sealed, dry, light-protected environment. A 1% liquid or other formulated presentation requires separate stability data because solvent, pH, preservative, container and headspace can alter degradation behaviour.spartalabs+1

Recommended controls include:

  • Store lyophilised Semax at βˆ’20Β°C unless the CoA specifies otherwise.

  • Store a liquid 1% preparation according to its formulation-specific CoA.

  • Protect both powder and liquid from direct light and excessive heat.

  • Keep containers tightly closed and minimise moisture or air exposure.

  • Allow sealed refrigerated or frozen containers to equilibrate before opening to reduce condensation.

  • Use low-binding materials where adsorption could affect recovery.

  • Prepare aliquots only when compatible with the documented formulation.

  • Store opened or reconstituted material at 2–8Β°C only where validated.

  • Avoid repeated freeze–thaw cycles.

  • Record formulation, active content, solvent, preparation date, operator and storage history.

Methionine oxidation is a relevant chemical pathway for Semax. Monitoring should include appropriate chromatographic and mass-spectral markers. In a 1% solution, apparent concentration changes may also arise from adsorption, precipitation, evaporation or non-uniform mixing.

If the product is a dry formulation, reconstitution should follow a validated laboratory procedure. If it is already a 1% liquid preparation, additional dilution should be performed only after confirming the matrix, pH, preservative and compatibility with the intended method. Do not assume that a liquid Semax product is interchangeable with a dry peptide or bacteriostatic-water presentation.

Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.

Technical Specifications and Molecular Attributes

Attribute Specification
Product Semax, 1% presentation, 60 mg nominal product quantity
Identity requiring confirmation Whether 60 mg refers to total formulation or active peptide
Common designation Semax; ACTH(4–10) Pro-Gly-Pro
Sequence H-Met-Glu-His-Phe-Pro-Gly-Pro-OH
Residue count 7 amino acids
IUPAC name Full systematic peptide name should be confirmed on the CoA; sequence notation is preferred for procurement
CAS Registry Number 80714-61-0 for commonly reported free Semax
Molecular formula, free peptide C₃₇H₅₁N₉O₁₀S
Average molecular mass, free peptide Approximately 813.9 g/mol
Exact mass, free peptide Approximately 813.3480 Da
Physical state and colour Lyophilised white to off-white solid or formulation-dependent clear liquid
Formulation content If 1% w/w and 60 mg total product: nominally 0.6 mg Semax; verify the label and CoA
Solubility profile Formulation- and matrix-dependent; solvent compatibility requires validation
Typical purity Proposed target β‰₯99.0% by RP-HPLC for peptide fraction
Identity testing LC-MS, ESI-MS or high-resolution MS
Long-term storage Typically βˆ’20Β°C for dry peptide; follow formulation-specific CoA for liquid material

The free-peptide sequence, formula, mass and CAS number are supported by public chemical and research references. Semax acetate and N-acetylated derivatives have different specifications, so the product form must be stated unambiguously.artemispeptides+2

Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents

Pharma Research .eu can position Semax as a documented European laboratory reagent, provided the 1% concentration and 60 mg presentation are defined precisely before publication. The product file should include the exact peptide mass, total formulation mass or volume, solvent and excipients, batch-specific CoA, SDS, sequence designation, purity result, active-content assay, identity data and storage instructions.

Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.

A quality-focused supplier should be able to discuss:

  • Whether the 1% designation is w/w or w/v.

  • Whether 60 mg refers to active Semax or total product.

  • Free Semax versus Semax acetate or modified analogues.

  • RP-HPLC purity and LC-MS identity testing.

  • Active-content assay and formulation uniformity.

  • Residual solvents, moisture and elemental-impurity reporting.

  • Container-closure integrity and light protection.

  • Storage, transport and documentation requirements.

Until the concentration basis and product matrix are confirmed, the item should be described as a Semax 1% research formulation with active content pending batch verification, rather than as an analytically complete 60 mg peptide product. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy Semax 1%, 60 mg”

Your email address will not be published. Required fields are marked *

Shipping & Delivery

MAECENAS IACULIS

Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.

ADIPISCING CONVALLIS BULUM

  • Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
  • Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
  • Diam parturient dictumst parturient scelerisque nibh lectus.

Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueΒ vestibulum amet elit ut volutpat.